Trends of China Monoclonal Antibody Industry Market 2014

1. Research on China Monoclonal Antibody (McAB) Industry, 2014 Published: Huidian Research No of pages: 60 Date: July 2014

2. Table Of Content Overview of Monoclonal Antibody  Operation Environment of China's Monoclonal Antibody Industry Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry Operation Situation of China's Monoclonal Antibody Industry China's Key Monoclonal Antibody Agent Enterprises Huge Growth Potential and Development Opportunities of China Monoclonal Antibody Market in the Future  Get full TOC at: http://www.reportsandintelligence.com/research-on-china-monoclonal-antibody-mcab-industry-2014-2018-reports-market/table-of-contents

3. Description Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China’s monoclonal antibody industry. Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in purchasing GenorBiopharma Co., Ltd, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient. Detailed Report at: http://www.reportsandintelligence.com/research-on-china-monoclonal-antibody-mcab-industry-2014-2018-market

4. Description The market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle. Due to late state, China’s strength on research and development will be still vulnerable within future three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume were far less than that of European and American countries. According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are independently researched drugs. Enquire about Report at: http://www.reportsandintelligence.com/enquire-about-report/114250

5. Similar Reports Research on Automotive Drive Shaft Market in China, 2014-2018 http://www.reportsandintelligence.com/research-on-automotive-drive-shaft-in-china-2014-2018-reports-market Research and Development Forecast of Core Drilling Rig Market in China, 2014 http://www.reportsandintelligence.com/research-and-development-forecast-of-core-drilling-rig-in-china-2014-reports-market

6. FOR MORE DETAILS Visit us at : http://www.reportsandintelligence.com/research-on-china-monoclonal-antibody-mcab-industry-2014-2018-market Stay With Us: • TELEPHONE: Direct: +1 (617) 674-4143 • Toll Free: +1 (855) 711-1555E-MAIL: sales@reportsandintelligence.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States